Re-emergence of an "Orphan" Test for Pulmonary Embolism
O ften clinically suspected, pulmonary embolism (PE) is a potentially fatal disease. Because highly effective but hazardous therapy exists, accurate diagnosis is extremely important. Indeed, much of the research and publications on PE, such as the Prospective Investigation of Pulmonary Embolism Diagnosis study, pertain mainly to methods of diagnosis.
Prior to the development of imaging techniques, the diagnosis of PE was based on a triad of dyspnea, hemoptysis, and chest pain, later shown to be nonspecific and unreliable, for the clinical spectrum can range from no symptoms at all to sudden death. The chest radiograph has been equally nonspecific and unreliable in diagnosis of PE.
In 1959, turning to the burgeoning field of clinical pulmonary physiology, Eugene Robin et al 1 suggested, "a physiologic approach to the diagnosis of pulmonary embolism" based on the Bohr equation. The simple concept utilized was that embolized parts of the lung are ventilated but not perfused so that alveolar CO 2 tension in these areas is low. Mixing of gas from perfused and unperfused units leads to an alveolar (measured as end-tidal) Pco 2 abnormally lower than arterial Pco 2 . In practice, an arterialalveolar CO 2 gradient of Ͼ 5 mm Hg was considered abnormal. In 10 patients with clinically suspected PE studied by Robin et al, 1 a gradient of that magnitude was found in 7 patients (and in 5 of 10 patients in a subsequent publication from the same institution). 2 The authors stated that this test is useful to diagnose large emboli only. They also indicated that the test is nonspecific and could be abnormal in the presence of rapid, shallow breathing of any cause, or a variety of other lung diseases.
In 1962, Colp and Williams 3 reported an arterialalveolar (A-a) gradient of Ͼ 5 mm Hg in only three of seven patients with clinical diagnosis of PE. These patients were studied more than a week after onset of symptoms, and it was pointed out that with time both clot lysis and collateral circulation would minimize the gradient. In support of this, one of the patients was restudied after another PE had occurred, and his A-a gradient was abnormal. Also, decreased ventilation due to atelectasis, bronchoconstriction, pleurisy, or infarction would diminish the gradient.
Hatle and Rokseth 4 studied patients whose diagnosis was confirmed by angiogram or at postmortem. They also note lack of an abnormal A-a gradient with small emboli or with passage of time since embolization; however, all but one of their patients with large PE had gradients Ͼ 5 mm Hg. These authors note that false-positive results in patients with COPD, pneumonias, congestive heart failure, or nonembolic shock could be corrected by having the patient expire fully and using end-expired rather than end-tidal CO 2 measurement in the calculation. (A significant difference between end-tidal and endexpired CO 2 is due to uneven ventilation and should not occur in normal subjects or those with PE).
Due to all of these problems with the alveolar dead space test proposed by the late Dr. Robin, in 1977 he eschewed it. He wrote an editorial 5 titled, "The Emperor May Have No Clothes," in which he discussed overdiagnosis of PE, overreliance on the then-popular ventilation-perfusion scan (which is merely an imaging method of detecting alveolar dead space), and the need for frequent pulmonary angiography. In this editorial, he did not even mention capnographic measurement of alveolar dead space or CO 2 gradient! Therefore, this test, which he fathered, now became an "orphan" test.
More recently, in 1986, Burki 6 resurrected the orphan but calculated physiologic dead space based on expired CO 2 instead of alveolar. They reported a dead space ratio of Ͼ 40% in all of 16 patients with abnormal angiograms. Twenty-nine patients with normal perfusion lung scan results had either normal dead space ratio or abnormal spirometry findings (thought to represent some lung disease other than CHEST / 120 / 1 / JULY, 2001 PE). In fact, many patients with PE will be unable to perform spirometry or will have abnormal spirometry results, perhaps due to splinting, pleurisy, etc.
In the 1990s, the orphan test has been adopted in a new way. Proposed by Kline et al 7 in 1997 and now by Rodger and colleagues in this issue of CHEST (see page 115), alveolar dead space calculation, based on arterial and end-tidal CO 2 , is used only to exclude PE. In order to improve sensitivity, a rather low limit of 15% is set for an abnormal result, and the test is combined with the D-dimer determination, which also has a low specificity but good sensitivity. By combining the two tests, both to be performed in the emergency department or hospital bedside, it is hoped that PE can be ruled out with enough confidence in many patients so as to obviate the need for the more expensive, time-consuming radiologic tests that are often difficult to arrange. Theoretically, this certainly sounds like a very good idea. However, further testing is necessary to ensure that small emboli are not missed by this technique, as patients with small emboli still must be treated to prevent recurrence, with its attendant morbidity and possible sudden mortality.
Also, as the authors point out, the capnographic studies require a fairly cooperative patient who can achieve a steady state, careful calibration of the equipment, and staff experienced with this test available on all shifts. In practice, each institution would have to validate this testing initially with full workup of all patients, both positive and apparently negative. Finally, another problem may prevent readoption of this orphan: unlike the well-established radiologic procedures, capnographic studies might present billing difficulties for some institutions. 
